Abbvie Inc

NYSE: ABBV
$175.17
-$3.33 (-1.9%)
Closing Price on January 10, 2025

ABBV Articles

The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Attaining a certain drug can mean the difference between...
These four Jefferies Franchise Picks are rated Buy and pay the highest dividends. They make good sense for investors now.
The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
Now all investor eyes turn to first-quarter earnings results. With interest rates still very low, investors looking to add capital should still focus on top dividend-paying stocks.
Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes...
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest decreased.
In a recent research report, Jefferiesfocused on some large cap stocks that are still trading way below their 52-week highs.
The top analyst upgrades, downgrades and initiations seen from Monday, March 7, include Enbridge, Micron Technology, Sun Life Financial, Starbucks, Stratasys and Wynn Resorts.
The top analyst upgrades, downgrades and initiations seen from Friday, February 26, include American Water Works, Autodesk, Kraft Heinz, Palo Alto Networks, Toyota and Vipshop.
The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest increased.
These stocks make good sense for long-term patient investors that have a growth and income total return bias in their portfolios.
The top analyst upgrades, downgrades and initiations seen on Tuesday, February 23, include Annaly Capital Management, Barrick Gold, Cheniere Energy, Fitbit, Dean Foods, Groupon, SolarCity, Twitter...
In a new research report, Jefferies shuffles some of the pharmaceutical stocks in its coverage universe and a beaten-down dividend leader is now the top pick globally.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.